Clinical Trial

Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma

Study acronym: TRUST
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study encompasses two multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trials to assess the antitumor activity of bintrafusp alfa in association with doxorubicin
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-25
Trial Details
NCT Number NCT04874311
Lead Sponsor Institut Bergonié
Collaborators: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Conditions Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
Enrollment 80 participants
Start Date 2022-03-01
Primary Completion 2027-01 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-24